Roche (ROG) Status Update summary

Neurology franchise and financial highlights

• Neurology sales contributed 20% of 2024 pharma sales, with double-digit growth expected, led by Ocrevus, Evrysdi, Enspryng, and Elevidys, and supported by a robust pipeline.

• Ocrevus franchise is projected to peak at $8.5 billion in 2029, with CHF 6.7 bn (+9%) in 2024 and subcutaneous formulation extending protection beyond patent expiry.

• Elevidys gene therapy for DMD is the first approved, with peak sales guidance of $2–3 billion, and CHF 0.2 bn in 2024.

• Roche maintains a leading global position in neurology, with high patient satisfaction and ongoing label expansions.

• No changes to peak sales guidance for Elevidys or Ocrevus, with continued confidence in the neurology franchise's growth trajectory.

Prasinezumab in Parkinson's disease (PADOVA Ph2b)

• PADOVA study in early-stage PD showed prasinezumab trended toward delaying motor progression, especially in L-DOPA subgroup (HR=0.76, p=0.0175), but missed the primary endpoint overall.

• Exploratory analyses at 104 weeks showed significant reduction in motor progression (–2.18 points, p=0.0117) and favorable safety profile.

• Biomarker evidence suggested potential impact on underlying pathology; high retention and rollover in open-label extension.

• Next steps for prasinezumab are under consideration, with novel trial design enabling future studies on top of standard-of-care.

• Prasinezumab's future development will be decided after further data review later this year.

Trontinemab in Alzheimer's disease (Brainshuttle™ platform)

• Trontinemab, a bispecific antibody using Brainshuttle technology, demonstrated rapid and deep amyloid PET reduction at 3.6 mg/kg (81% amyloid PET negative at 28 weeks).

• Early and pronounced effects were observed on CSF and plasma biomarkers, including >50% reduction in plasma pTau217 at 6 months.

• Favourable safety and tolerability profile with low ARIA incidence (<5%), limited transient anemia, and manageable infusion reactions, even in high-risk APOE4 carriers.

• Phase III initiation is planned for later this year or in 2025, with further details to be shared at upcoming conferences.